ArticleArteriosclerosis, thrombosis, and vascular biology2015
Local MicroRNA Modulation Using a Novel Anti-miR-21-Eluting Stent Effectively Prevents Experimental In-Stent Restenosis.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Arteriosclerosis, thrombosis, and vascular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 67 papers.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 122 citations in OpenAlex.
- Are RNA Therapies a Solid Foundation or a Frontier Yet to Be Conquered?International journal of molecular sciences · 2026Review
- Decoding Vascular Senescence: Cellular Insights and Therapeutic Strategies.International journal of biological sciences · 2026Review
- Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches.Current atherosclerosis reports · 2024Review
- Differential responses to thrombospondin-1 and PDGF-BB in smooth muscle cells from atherosclerotic coronary arteries and internal thoracic arteries.Scientific reports · 2024Article
- MicroRNAs and Cardiovascular Disease Risk.Current cardiology reports · 2024Review
- Similarities and Differences of Vascular Calcification in Diabetes and Chronic Kidney Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Incidence, risk factors, and clinical sequelae of incomplete stent apposition after sirolimus-eluting stent.The international journal of cardiovascular imaging · 2023Article
- The Roles of microRNAs in the Cardiovascular System.International journal of molecular sciences · 2023Review
- MicroRNA regulation of phenotypic transformations in vascular smooth muscle: relevance to vascular remodeling.Cellular and molecular life sciences : CMLS · 2023Review
- Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review.Biology · 2023Review
- miR579-3p is an inhibitory modulator of neointimal hyperplasia and transcription factors c-MYB and KLF4.Cell death discovery · 2023Article
- Review
- Inflammatory microRNAs in cardiovascular pathology: another brick in the wall.Frontiers in immunology · 2023Review
- Cardiac microRNAs: diagnostic and therapeutic potential.Archives of medical science : AMS · 2023Article
- Noncoding RNAs in Vascular Cell Biology and Restenosis.Biology · 2022Review
- Clinical Application of Serum microRNAs in Atherosclerotic Coronary Artery Disease.Journal of clinical medicine · 2022Review
- Epigenetic Modifications and Non-Coding RNA in Diabetes-Mellitus-Induced Coronary Artery Disease: Pathophysiological Link and New Therapeutic Frontiers.International journal of molecular sciences · 2022Review
- Two-stage degradation and novel functional endothelium characteristics of a 3-D printed bioresorbable scaffold.Bioactive materials · 2022Article
- MicroRNAs in cardiovascular diseases.Medical review (2021) · 2022Review
- Metformin: Expanding the Scope of Application-Starting Earlier than Yesterday, Canceling Later.International journal of molecular sciences · 2022Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issuedCorrection.2015
Authors and funding
17 authors at 6 institutions in 4 countries.
Dong WangFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Tobias DeuseFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Mandy StubbendorffFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Ekaterina ChernogubovaFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Reinhold G ErbenFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Suzanne M EkenFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Hong JinFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Yuhuang LiFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Albert BuschFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Christian-H HeegerFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Boris BehnischFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Hermann ReichenspurnerFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Robert C RobbinsFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Joshua M SpinFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Philip S TsaoFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
Sonja SchrepferFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.). schrepfer@stanford.edu.
Lars MaegdefesselFrom the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
University Medical Center Hamburg-Eppendorf · DEVA Palo Alto Health Care System · USUniversität Hamburg · DEKarolinska Institutet · SEStanford University · USTransTissue (Germany) · DE
Funding
Insulin Resistance, Vascular Stiffness, and HypertensionR01HL105299 · NHLBI · STANFORD UNIVERSITY · PI TSAO, PHILIP S · 2010 to 2013
$1.6MMicroRNA Regulation of Nicotine Accelerated AAAsR01HL122939 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI TSAO, PHILIP S · 2014 to 2017
$1.4MNHLBI NIH HHS 1HL-105299NHLBI NIH HHS 1HL122939NHLBI NIH HHS R01 HL105299NHLBI NIH HHS R01 HL122939
Abstract
objectiveDespite advances in stent technology for vascular interventions, in-stent restenosis (ISR) because of myointimal hyperplasia remains a major complication. APPROACH AND
resultsWe investigated the regulatory role of microRNAs in myointimal hyperplasia/ISR, using a humanized animal model in which balloon-injured human internal mammary arteries with or without stenting were transplanted into Rowett nude rats, followed by microRNA profiling. miR-21 was the only significantly upregulated candidate. In addition, miR-21 expression was increased in human tissue samples from patients with ISR compared with coronary artery disease specimen. We systemically repressed miR-21 via intravenous fluorescein-tagged-locked nucleic acid-anti-miR-21 (anti-21) in our humanized myointimal hyperplasia model. As expected, suppression of vascular miR-21 correlated dose dependently with reduced luminal obliteration. Furthermore, anti-21 did not impede reendothelialization. However, systemic anti-miR-21 had substantial off-target effects, lowering miR-21 expression in liver, heart, lung, and kidney with concomitant increase in serum creatinine levels. We therefore assessed the feasibility of local miR-21 suppression using anti-21-coated stents. Compared with bare-metal stents, anti-21-coated stents effectively reduced ISR, whereas no significant off-target effects could be observed.
conclusionThis study demonstrates the efficacy of an anti-miR-coated stent for the reduction of ISR.
Indexed as
Coated Materials, BiocompatibleGene Expression RegulationAnimalsAntibodies, AntinuclearCell ProliferationCoronary RestenosisCoronary VesselsDisease Models, AnimalDrug-Eluting StentsFemaleGraft Occlusion, VascularHumansMaleMicroRNAsMicroscopy, Electron, ScanningMiddle AgedAntibodies, AntinuclearCoated Materials, BiocompatibleMicroRNAsMIRN21 microRNA, mousecoronary restenosishyperplasiamicroRNAsratsstents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.